Organisation paid for research Program year 2022 Source: CMS Open Payments

Wee Care Pediatrics Roy

Neither a doctor nor a teaching hospital

Research payments

$527,865

142 payments

Through program year 2022, Wee Care Pediatrics Roy is reported as receiving $527,865 in research payments, across 142 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$20,037	4
2021	Research	$104,961	6
2020	Research	$290,177	67
2019	Research	$112,691	65

Breakdown

Who paid Research payments · program years 2019–2022

Merck Sharp & Dohme Corporation $447,559 132 payments
Pfizer Inc. $80,307 10 payments

Studies the money was for Research payments · program years 2019–2022

A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED $336,923 21 payments
A Phase 2B Randomized Observerblinded Trial to Describe the Safety Tolerability and Immunogenicity of Menabcwy Administered on 2 Different Dosing Schedules in Healthy Participants 11 to 15 Years of Age $80,307 10 payments
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants $57,966 6 payments
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED $30,077 82 payments
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II $16,977 8 payments
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED $5,428 14 payments
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants PNEU-LINK $186 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.